Novocure Secures New $150 Million Non-Dilutive Term Loan Financing
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in full Novocure’s existing $100 million term loan debt and fund working capital. The agreement improves upon the pricing and terms of Novocure’s existing credit facility with BioPharma Secured Investments III Holdings Cayman LP and extends the maturity of Novocure’s debt until February 2023. Additional information on the term loan agreement will be filed with the U.S. Securities and Exchange Commission as a Current Report on Form 8-K. “Novocure is a global oncology company with a proprietary platform technology, and we are pleased to further strengthen our cash position with non-dilutive capital,” said Wilco Groenhuysen, Novocure’s Chief Financial Off
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024Business Wire
- NovoCure Limited (NASDAQ: NVCR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock, up previously from $25.00.MarketBeat
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024Business Wire
- NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an "overweight" rating on the stock.MarketBeat
NVCR
Earnings
- 2/22/24 - Beat
NVCR
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- 4/12/24 - Form PRE
- NVCR's page on the SEC website